<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498016</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-Busulfan</org_study_id>
    <nct_id>NCT01498016</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia</brief_title>
  <official_title>Pharmacokinetic Study of Intravenous Busulfan as Conditioning Regimen for Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous Busulfan (iv-Bu) is commonly used as part of preparation regimen for allogeneic&#xD;
      hematopoietic stem cell transplantation for patients with acute leukemia. Though the&#xD;
      pharmacokinetics data are available for population from America, Europe and Japan or Korea in&#xD;
      Asia, there are no data in Chinese population. It is shown that high Bu concentration are&#xD;
      associated with the toxicity such as veno-occlusion disease and lower concentration is&#xD;
      correlated with reduced anti-leukemia effect, thus the monitoring of Bu and/or the strategy&#xD;
      to achieve an optimal target Bu concentration are accepted to avoid toxicity while maintain&#xD;
      the anti-leukemia effect which may overall improve the outcome of allo-SCT. Thus we conduct&#xD;
      the pharmacokinetic study in Chinese population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received intravenous Busulfan based conditioning regimen for allogeneic stem&#xD;
      cell transplantation.&#xD;
&#xD;
      Intravenous Busulfan (iv-Bu) was given 1.6mg/kg twice daily for 4 days as in the conditioning&#xD;
      regimen.&#xD;
&#xD;
      Blood samples were obtained after first and 7th dose of iv Bulsulfan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>predose, 0,1,2,3,4,6,8,12,24,48,72, 96 hours post-dose</time_frame>
    <description>busulifan blood concentration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>Iv-Busulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iv busulfan 1.6mg/kg given q12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Iv busulfan 1.6mg/kg q12h D1- D4</description>
    <arm_group_label>Iv-Busulfan</arm_group_label>
    <other_name>study group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with acute myeloid or lymphoblastic leukemia in 1st or second remission&#xD;
&#xD;
          -  age 18-55 years&#xD;
&#xD;
          -  with inform consent&#xD;
&#xD;
          -  no contraindication for allogeneic transplantation: active infection, allergy to&#xD;
             FLu/Bu/CTX, liver and renal function damage&#xD;
&#xD;
          -  HLA matched related (6/6) or unrelated donors (at least 8/10)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age less than 18 years or over 56 years&#xD;
&#xD;
          -  HLA mismatched related donor&#xD;
&#xD;
          -  liver function/renal function damage (over 2 X upper normal range)&#xD;
&#xD;
          -  with mental disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong HU, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rui Jin Hospital, Shanghai JiaoTong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiong HU, M.D.</last_name>
    <phone>86-21-64370045-601818</phone>
    <email>hujiong@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601818</phone_ext>
      <email>hujiong@medmail.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 19, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood &amp;^ Marrow Transplantation Center</investigator_title>
  </responsible_party>
  <keyword>acute leukemia</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>busulfan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

